Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison

Yoon K Loke, Shiva Pradhan, Jessica Ka-Yan Yeong, Chun Shing Kwok

Research output: Contribution to journalArticlepeer-review

46 Citations (Scopus)


There are concerns regarding increased risk of acute coronary syndrome with dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban or apixaban carry a similar risk as compared to dabigatran.
Original languageEnglish
Pages (from-to)707–717
Number of pages11
JournalBritish Journal of Clinical Pharmacology
Issue number4
Early online date11 Mar 2014
Publication statusPublished - Oct 2014


  • acute coronary syndrome
  • apixaban
  • dabigatran

Cite this